Bailard’s Arbutus Biopharma ABUS Stock Holding History

Bailard’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-228,000	Closed	-$816K	–	540
2019 Q1	$816K	Buy	228,000 +12,000	+6%	+$46.1K	0.05%	243
2018 Q4	$827K	Buy	216,000 +146,000	+209%	+$719K	0.06%	233
2018 Q3	$662K	Buy	+70,000	New	+$695K	0.04%	291
2016 Q4	–	Sell	-215,000	Closed	-$740K	–	302
2016 Q3	$740K	Hold	215,000	–	–	0.07%	183
2016 Q2	$748K	Hold	215,000	–	–	0.09%	172
2016 Q1	$888K	Buy	+215,000	New	+$768K	0.12%	115
2015 Q4	–	Sell	-215,000	Closed	-$1.31M	–	204
2015 Q3	$1.31M	Buy	215,000 +76,000	+55%	+$674K	0.2%	76
2015 Q2	$1.65M	Hold	139,000	–	–	0.25%	70
2015 Q1	$2.43M	Buy	139,000 +59,000	+74%	+$1.21M	0.34%	46
2014 Q4	$1.21M	Buy	+80,000	New	+$1.38M	0.17%	88
2014 Q2	–	Sell	-95,500	Closed	-$2.05M	–	235
2014 Q1	$2.05M	Sell	95,500 -20,295	-18%	-$365K	0.33%	51
2013 Q4	$923K	Buy	+115,795	New	+$965K	0.15%	89

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's ABUS Position: Q2 2019 in Review

Bailard sold out of Arbutus Biopharma (ABUS) in Q2 2019, closing a stake of 228,000 shares — an estimated $816K sold.

Bailard first reported a position in ABUS in Q4 2013 and held it in 12 quarters. The position peaked at $2.43M in Q1 2015. 62 funds tracked by Wall St. Rank hold ABUS as of Q2 2019.

Bailard reported no remaining Arbutus Biopharma position as of Q2 2019 after selling out during the quarter.
Bailard sold 228,000 Arbutus Biopharma shares in Q2 2019, an estimated $816K.
Bailard first reported a position in Arbutus Biopharma in Q4 2013 and held it in 12 quarters.
Bailard's Arbutus Biopharma position peaked at $2.43M in Q1 2015.
62 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2019.

Based on Bailard's 13F filing for Q2 2019, filed 26 Jul 2019.